$SGMT
Sagimet Biosciences Inc. Series A Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Sagimet Biosciences Inc. Series A Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is SGMT down today? It is at $9.07 (-5.61%), and our scanner flagged it 135 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment SGMT spikes, and full due diligence on SGMT — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $SGMT 135 times in the last 30 days. Create a free account to track $SGMT, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
The market is closed. Here is how SGMT traded in the last session, Friday (last price and move above). Our scanner fired 19 unusual-volume and momentum alerts on SGMT on Friday, peaking at 61.5x its normal volume.
Likely catalystSagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesReported Completed underwritten offering of Series A Common Stock and pre-funded warrants in October, with gross proceeds of $115 millionReported Venereology (EADV) Congress. Denifanstat showed progressive and sustained improvements across all efficacy endpoints in the open-label extension, including Investigator’s Global Assessment (IGA) success with a response rate of 57%, 72%Reported $16.3 million and $34.9 million, respectively, compared to $9.7 million and $32.3 million for the three and nine months ended September 30, 2025, respectively., from an SEC filing. Read it →Latest filingSC 13GPassive 5%+ stake disclosedNov 16, 2026 · 4 days agoThe company can keep selling new shares into the market. Size not stated in the filing.
Some filings did not state a size, so these are floors.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
At-the-market (ATM) program — sells new shares into the market gradually over time
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Kemble George Director | Sold (automatic/other) | -351K 1.1% of company | sold 85% | 62K | $3.6M at $10.23 | Aug 14, 26 |
Kemble George Director | Other | 351K 1.1% of company | added 100% | 413K | $2.2M at $6.36 | Aug 14, 26 |
Kemble George Director | Sold (automatic/other) | -20K 0.07% of company | sold 25% | 62K | $201K at $9.95 | Aug 11, 26 |
Kemble George Director | Other | 20K 0.07% of company | added 33% | 82K | $129K at $6.36 | Aug 11, 26 |
Kemble George Director | Sold (automatic/other) | -19K 0.06% of company | sold 23% | 62K | $141K at $7.46 | Jul 20, 26 |
Rozek Elizabeth Officer | Sold (automatic/other) | -11K 0.03% of company | sold 4.5% | 224K | $82K at $7.76 | Jul 20, 26 |
Happel David Officer | Sold (automatic/other) | -64K 0.2% of company | sold 8.0% | 742K | $497K at $7.76 | Jul 20, 26 |
Chauche Thierry Officer | Acquired (grant/award) | +44K 0.1% of company | added 100% | 60K | n/a | Feb 19, 26 |
Happel David Officer | Acquired (grant/award) | +128K 0.4% of company | added 19% | 806K | n/a | Feb 19, 26 |
Martins Eduardo Bruno Officer | Acquired (grant/award) | +44K 0.1% of company | added 43% | 147K | n/a | Feb 19, 26 |
Rozek Elizabeth Officer | Acquired (grant/award) | +44K 0.1% of company | added 23% | 235K | n/a | Feb 19, 26 |
Rozek Elizabeth Officer | Sold (automatic/other) | -3K | sold 1.4% | 191K | $14K at $5.36 | Feb 10, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.

The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
The market is closed. Here is how SGMT traded in the last session, Friday (last price and move above). Our scanner fired 19 unusual-volume and momentum alerts on SGMT on Friday, peaking at 61.5x its normal volume.
SGMT last traded at $9.07, down 5.61% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
The SGMT Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged SGMT 135 times in the last 30 days.
SGMT (Sagimet Biosciences Inc. Series A Common Stock) trades on XNAS, with a market cap of about $279M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge SGMT for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$SGMT discussion
Sign in to ask a question or join the discussion.